Fairvalue-Calculator Fairvalue-Calculator
EN DE

Delcath Systems, Inc (DCTH) Fair Value & Analysis

Healthcare · US · Market cap $404M

Price$12.29
Fair Value$2.74
Upside-77.7%
Quality95/100
Evidence: High Range $2.27 – $3.56

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Delcath Systems, Inc (DCTH) currently trades at $12.29, while our model-based Fair Value estimate is $2.74 — implying the stock looks roughly 77.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Delcath Systems, Inc (DCTH) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.74 versus a price of $12.29 — about −78% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DCTH?
Our 21-model fair value for Delcath Systems, Inc is $2.74 (as of Jun 24, 2026), built from audited fundamentals. The current price is $12.29.
What is the quality score of DCTH?
Delcath Systems, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.